EPA-1128 – Long-acting second-generation antipsychotics: Improving subjective experience of pharmacological treatment and quality of life

Abstract

Long-acting injectable (LAI) antipsychotics have been used as an alternative to oral antipsychotic formulations. to evaluate the impact of switching to a LAI second-generation antipsychotic (SGA) in terms of changes in patient's psychopathology, subjective experience of drug and quality of life. 18 adult outpatients diagnosed with Schizoaffective disorder (by means of the SCID-I/P) and attending the Psychiatric Unit of the University of Florence were recruited. All patients were under a stabilized therapy with a single oral SGA (either olanzapine or paliperidone) and were switched to its corresponding LAI formulation (olanzapine pamoate or paliperidone palmitate). Patients were assessed by means of the following questionnaires: MADRS, YMRS, PANSS, DAI-10, SWN and SF-36 at enrolment (T0) and after 6 months (T1). A significant reduction was found between T0 and T1 (p<.05) in PANSS total, negative and general psychopathology mean scores, as well as in mean MADRS and YMRS total scores. No difference was found for positive PANSS mean scores. We observed a significant increase of mean DAI-10 and SWN total scores between T0 and T1 (p<.05). A reduction of side effects like sedation and blunted affect between T0 and T1 (p<.05) was confirmed by significant increases in mean SF-36 subscales scores, such as: general health (p<.01) change in health (p<.01) and social integration (p<.05). Treatment with LAI SGAs seems to be a valid alternative in patients with Schizoaffective disorder. Our preliminary data suggest an improvement in patient's subjective experience of pharmacological therapy and health-related quality of life, together with a similar efficacy on psychopathology.